Guidance needed to ensure EU’s JCA improves access to innovative cancer treatments

Joint Clinical Assessments (JCA) can support getting new innovative cancer medicines to patients faster, if the right balance in evidence generation and assessment to facilitate national decisions on access for these innovations can be found.

This is the main conclusion from a new  report developed by Evidera, and commissioned by the pharma trade lobby the European Federation of Pharmaceutical Industries and Association (EFPIA) Oncology Platform.

The EFPIA’s aspiration is to get the latest advances in cancer treatment to patients as quickly as possible. With less than one year to go before the new system is applied to oncology medicines and advanced therapy medicinal products (ATMPs), health technology developers (HTDs) are urgently seeking transparent, pragmatic and evidence-based guidance on how the changes will impact the development, assessment and subsequent introduction of new medicines in national healthcare systems.